To,
All the Stakeholders of IPC

NOTICE

We all are aware that Novel Coronavirus Disease (COVID-19) outbreak has been declared as pandemic by the World Health Organization and in order to protect the country and each of its citizens, Hon’ble Prime Minister of India has announced nationwide lockdown till 3rd May, 2020. Being an autonomous Institute under the Ministry of Health & Family Welfare, Government of India, the Indian Pharmacopoeia Commission (IPC) is actively engaged in providing important healthcare related services to the country including the development, certification, and distribution of reference substances.

In order to better combat the threat of the COVID 19, hydroxy-chloroquine has been recommended as a prophylactic drug of choice for asymptomatic healthcare workers involved in the care of suspected or confirmed cases of COVID-19, and asymptomatic household contacts of laboratory confirmed cases. India has emerged as the leading manufacturer of hydroxy-chloroquine and supplying the same to countries across the globe.

In view of above, IPC has successfully developed the IP Reference Substance (IPRS) of hydroxy-chloroquine sulphate which is available for sale and distribution from IPC. The details of the same may be found at our website www.ipc.gov.in. In addition, IPC is continuing with providing other IPRS, including those of the anti-retroviral drugs, to our stakeholders in the country.

For further information you may reach to us at lab.ipc@gov.in.

This issues with the approval of the competent authority.

Sd/-

(Dr. Robin Kumar)
Principal Scientific Officer
for Secretary-cum-Scientific Director (I/c)

Copy for information to. Dr. Mandeep K. Bhandari, Joint Secretary (R), MoH&FW, Nirman Bhawan, New Delhi 110011.